Skip to main content
. Author manuscript; available in PMC: 2018 Aug 16.
Published in final edited form as: Genes Dis. 2016 Feb 21;3(2):114–123. doi: 10.1016/j.gendis.2016.02.002

Table 3.

HER2+ CSCs verus Non-HER2+ CSCs.

Parameter HER2+ CSC Non-HER2+ CSC
HER2 overexpression Observed Not observed
Subtypes Lumial A, Luminal B and HER2+ All subtypes
Anti-HER2 agents Effective for treatment Not effective for treatment
Phenotype High ALDH activity, mammosphere formation, invasiveness and tumorigenesis, as compared to Non-HER2+ CSC.
Higher self-renewal and replicative potential.		 Low ALDH activity, mammosphere formation, invasiveness and tumorigenesis, as compared to HER2+ CSC.
Lower self-renewal and replicative potential, as compared to HER2+ CSC.
Genotype Increased regulation of genes related to stem cells and progenitor cell control. Increased expression of genes related to S/G2/M transition. Reduced expression of genes involved in differentiation and immune response. Decreased regulation of genes related to stem cells and progenitor cell control, decreased expression of genes related to S/G2/M transition. Increased expression of genes involved in differentiation and immune response, as compared to HER2+ CSC.